---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-270524"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T22:55:17.096406+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics reports Q3 2025 net income of $5.9M, cuts FY revenue guidance to $115-118M

## Summary
- Q3 revenue $30.6M (+20% YoY), net income $5.9M (doubled), adjusted net income $8.8M.
- Full-year revenue guidance lowered to $115-118M from $118-128M due to Etorel rollout delays.
- Nine-month 2025 revenue $79.4M, net income $11.2M vs $17.3M YoY; basic EPS $0.08.
- Cash $80.3M as of Sept 30; completed Phase 3 pneumoconiosis trial enrollment (272 patients).
- Hydronidone NDA in China progressing; US IND for MASH delayed to 2026.

## SEC filing metadata
- accession: 0001193125-25-270524
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/0001193125-25-270524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-270524
- JSON: https://secwatch.observer/filing/0001193125-25-270524.json
- Plain text: https://secwatch.observer/filing/0001193125-25-270524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.